Lyra Therapeutics, Inc. products

Lyra - Long-acting Mometasone Furoate

LYR-220, Lyra’s second product candidate, is in Phase 2 development for the millions of chronic rhinosinusitis (CRS) patients who have undergone a prior sinus surgery but continue to have persistent disease.

Lyra - Innovative Therapeutic Solution for CRS

Lyra’s lead product candidate, LYR-210, to treat chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses. LYR-210 is an anti-inflammatory implantable drug matrix based upon Lyra’s XTreo™ platform designed to elute mometasone furoate consistently and locally to the inflamed mucosal tissue of surgically-naïve CRS patients for up to six months from a single treatment. LYR-210 is being developed as an alternative to sinus surgery for CRS patients.